Foghorn Therapeutics, Inc. (FHTX) News
Filter FHTX News Items
FHTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FHTX News From Around the Web
Below are the latest news stories about Foghorn Therapeutics Inc that investors may wish to consider to help them evaluate FHTX as an investment opportunity.
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowFoghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
Foghorn Therapeutics Announces Chief Scientific Officer SuccessionCAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective today, January 10, 2022. Carl Decicco, Ph.D., is retiring from his role as Chief Scientific Officer at Fog |
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect ConferenceCAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10th through the 13th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform and resu |
Zacks: Analysts Expect Foghorn Therapeutics Inc. (NASDAQ:FHTX) Will Post Quarterly Sales of $330,000.00Equities research analysts expect that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will post sales of $330,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The firm is scheduled to issue [] |
Zacks: Analysts Anticipate Foghorn Therapeutics Inc. (NASDAQ:FHTX) to Post -$0.29 Earnings Per ShareAnalysts expect Foghorn Therapeutics Inc. (NASDAQ:FHTX) to post ($0.29) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Foghorn Therapeutics earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at $0.56. The business is scheduled to report its next [] |
Zacks: Analysts Anticipate Foghorn Therapeutics Inc. (NASDAQ:FHTX) Will Post Quarterly Sales of $330,000.00Brokerages predict that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will announce $330,000.00 in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The business is expected to announce its next quarterly earnings [] |
-$0.29 Earnings Per Share Expected for Foghorn Therapeutics Inc. (NASDAQ:FHTX) This QuarterEquities analysts predict that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will announce earnings per share of ($0.29) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Foghorn Therapeutics earnings, with the highest EPS estimate coming in at $0.56 and the lowest estimate coming in at ($0.72). The business is expected to [] |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, trader! |
58 Biggest Movers From YesterdayGainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% t... |